News

Western Uranium & Vanadium Corp. Secures CAD $5 Million Financing

Western Uranium & Vanadium Corp. Secures CAD $5 Million Financing

Western Uranium & Vanadium Corp. Closes First Tranche of Financing

Western Uranium & Vanadium Corp. (CSE: WUC) (OTCQX: WSTRF) is excited to reveal the successful closure of the first tranche of its brokered financing. This financing initiative was previously announced, setting the stage for substantial developments within the company.

Details of the Financing

In this first tranche, Western issued a total of 3,819,695 units, priced at CAD $1.32 per unit, resulting in approximate gross proceeds of CAD $5,041,998. Each unit comprises one common share and one purchase warrant, which is exercisable at CAD $1.78 for a duration of four years. The issuance of these units comes as the company strategically positions itself for future growth and opportunities.

Subscription Details and Regulations

The units were offered to Canadian purchasers under National Instrument 45-106 - Prospectus Exemptions and also to U.S. investors using available exemptions under the U.S. Securities Act of 1933. Investors located outside Canada were included under Ontario Securities Commission Rule 72-503, facilitating broader participation in this offering. Notably, a four-month statutory hold applies to securities issued to Canadian subscribers.

Related-Party Participation

In an interesting development, a director of the company participated by subscribing for 3,787 units, which qualifies as a related-party transaction as per Multilateral Instrument 61-101. The company relied on specific exemptions due to the limited impact of this participation on shareholders, ensuring compliance with regulatory requirements without extensive formal procedures.

Role of A.G.P. Canada Investment ULC

To facilitate this financing, Western engaged A.G.P. Canada Investment ULC as the sole agent and bookrunner. A commission amounting to 7% of the total proceeds from units placed was paid to A.G.P. Canada, highlighting a solid partnership in advancing the company's objectives.

Proceeds Utilization

Western intends to deploy the net proceeds from this offering towards expanding its production capabilities and enhancing mining operations at the Sunday Mine Complex. The funds will also support licensing and developing processing facilities, baseline data collection, and permitting for the San Rafael Project. Acquisitions of uranium and vanadium properties near existing sites and investments in mining equipment are also on the agenda.

Future Financing Prospects

Looking ahead, Western Uranium anticipates a second tranche of financing amounting to 346,971 units, potentially raising total gross proceeds to around CAD $5,500,000. This step is strategically timed to align with the brokerage processes of President’s List investors, and further announcements will be made once this tranche is closed.

Over-Allotment Option

The agreement also incorporates an over-allotment option allowing the placement of up to an additional 625,000 units, potentially boosting the company’s funds by CAD $825,000. This option must be exercised by December 23. Overall, this financing initiative is pivotal for Western Uranium's growth strategies and operational enhancements.

About Western Uranium & Vanadium Corp.

Western Uranium & Vanadium Corp. is focused on ramping up high-grade uranium and vanadium production, primarily from its Sunday Mine Complex, which is strategically located in the rich Uravan Mineral Belt. Their project pipeline also extends to several conventional sites in both Colorado and Utah. Furthermore, the Maverick Minerals Processing Plant is poised for licensing to implement advanced separation processes.

Frequently Asked Questions

What is the amount raised in the first tranche of financing?

The first tranche raised approximately CAD $5,041,998 through the issuance of 3,819,695 units.

What will be the proceeds from the financing used for?

The funds will be used for production expansion, mineral processing licensing, acquisition of properties, and general working capital.

Who acted as the sole agent for this financing?

A.G.P. Canada Investment ULC acted as the sole agent and bookrunner in this financing initiative.

Is there a related-party transaction in this offering?

Yes, a director of the company subscribed for 3,787 units, which is classified as a related-party transaction.

What is the second tranche expected to bring in?

The second tranche is expected to add up to 346,971 units, increasing total gross proceeds to approximately CAD $5,500,000.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 7

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 4

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 5

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 4

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 3

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 2

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 7

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 3

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading

Top 5 Most Recently Viewed Articles

Leadership Shift at Tourmaline Bio: CMO Resignation Announced

Updated Category News Views 119

Leadership Transition at Tourmaline Bio Tourmaline Bio, Inc. (NASDAQ:TRML) has recently revealed a significant change within its leadership. Dr. Yung Chyung, the Chief Medical Officer (CMO), is set to resign from his post effective at the end of October. This announcement took place in a recent filing, highlighting the company's commitment to transparency as it reshapes...

Continue Reading
Innovative Cancer Research by Compugen at Upcoming Conference

Updated Category News Views 118

Compugen to Showcase Groundbreaking Research in Cancer Immunotherapy Compugen Ltd. (Nasdaq: CGEN), a leading force in clinical-stage cancer immunotherapy, has announced an exciting opportunity to present at the upcoming Single Cell Genomics 2025 Conference. This event, scheduled for September 15-17, highlights advancements in genomics and how it intertwines with cancer...

Continue Reading
Transform Your Finances: The Journey of Salesforce Stock

Updated Category News Views 222

Transformational Growth of Salesforce Stock Over the past 15 years, Salesforce (NYSE: CRM) has emerged as a powerhouse in the tech industry, consistently surpassing market expectations. With an impressive average annual return rate of 22.25%, it has outperformed the broader market by 10.15% on an annualized basis. As of now, the company's market capitalization stands at...

Continue Reading
Infosys and AGCO Join Forces for Transformational Success

Updated Category News Views 185

Infosys and AGCO Team Up for IT and HR Transformation Building on a longstanding relationship to enhance AGCO's operational framework for growth by leveraging Infosys Cobalt and Infosys Topaz. Infosys (NSE: INFY), a global leader in next-generation digital services and consulting, has announced the continuation of its strategic partnership with AGCO Corporation (NYSE:...

Continue Reading
Transforming Europe's Contract Furniture Market with AI Strategies

Updated Category News Views 385

Growth of Europe's Contract Furniture Market The contract furniture and furnishing market in Europe is on the verge of a substantial transformation, anticipating an impressive growth of USD 4.75 billion from 2024 to 2028. The compound annual growth rate (CAGR) is expected to be close to 5.1% during this forecast period. This expansion is mainly driven by the increasing...

Continue Reading